WEKO3
アイテム
{"_buckets": {"deposit": "933a1f8f-361e-49fa-aa94-f0f82b5f42ec"}, "_deposit": {"id": "7201", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "7201"}, "status": "published"}, "_oai": {"id": "oai:soar-ir.repo.nii.ac.jp:00007201", "sets": ["849"]}, "author_link": ["17510", "17511", "17512", "17513", "17514", "17515", "17516", "17517"], "item_1628147817048": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_6_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2012-10-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "12", "bibliographicPageEnd": "2134", "bibliographicPageStart": "2130", "bibliographicVolumeNumber": "6", "bibliographic_titles": [{"bibliographic_title": "JOURNAL OF THORACIC ONCOLOGY"}]}]}, "item_6_description_19": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "This is a non-final version of an article published in final form in JOURNAL OF THORACIC ONCOLOGY. 6(12):2130-2134 (2011).", "subitem_description_type": "Other"}, {"subitem_description": "信州大学博士(医学)・学位論文・平成23年3月31日授与(甲第903号)・吾妻俊彦", "subitem_description_type": "Other"}]}, "item_6_description_20": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Introduction: Thymic carcinoma is a rare epithelial neoplasm that tends to be aggressive and metastasize widely. The optimal chemotherapy for unresectable advanced thymic carcinoma has not yet been established because of its rare occurrence. The purpose of this study was to evaluate the efficacy and tolerability of combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. Methods: A retrospective analysis of 34 patients with untreated and unresectable thymic carcinoma who received chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds between 1996 and 2010 was conducted. Twenty-nine patients were treated with a combination of cisplatin (50 mg/m(2)) and doxorubicin (40 mg/m(2)) on day 1, vincristine (0.6 mg/m(2)) on day 3, and cyclophosphamide (700 mg/m(2)) on day 4. Five patients were treated with carboplatin (area under the curve of 3.0 minutes center dot mg/ml) instead of cisplatin. Results: The responses of all 34 patients to the current regimen were assessed. The median number of treatment cycles for the present chemotherapy was 4. The overall response rate and disease control rate were 50.0% and 88.2%, respectively. The median survival was 21.3 months (95% confidence interval [CI], 15.0-37.2 months), and the 1-year and 3-year survival rates were 72.7% (95% CI, 56.8-88.6%) and 34.4% (95% CI, 16.2-52.6%), respectively. The most common adverse event was leukopenia/neutropenia, and nonhematological toxicities were mild. Conclusions: Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds is an effective and well-tolerated treatment for unresectable advanced thymic carcinoma.", "subitem_description_type": "Abstract"}]}, "item_6_description_30": {"attribute_name": "資源タイプ(コンテンツの種類)", "attribute_value_mlt": [{"subitem_description": "Article", "subitem_description_type": "Other"}]}, "item_6_link_3": {"attribute_name": "信州大学研究者総覧へのリンク", "attribute_value_mlt": [{"subitem_link_text": "Koizumi, Tomonobu", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.WakmHhkh.html"}, {"subitem_link_text": "Urushihata, Kazuhisa", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.jakhHVkh.html"}, {"subitem_link_text": "Yamamoto, Hiroshi", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.HVnhHVkh.html"}, {"subitem_link_text": "Hanaoka, Masayuki", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.yCLmHVkh.html"}]}, "item_6_link_67": {"attribute_name": "WoS", "attribute_value_mlt": [{"subitem_link_text": "Web of Science", "subitem_link_url": "http://gateway.isiknowledge.com/gateway/Gateway.cgi?\u0026GWVersion=2\u0026SrcAuth=ShinshuUniv\u0026SrcApp=ShinshuUniv\u0026DestLinkType=FullRecord\u0026DestApp=WOS\u0026KeyUT=000297974100023"}]}, "item_6_publisher_4": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "LIPPINCOTT WILLIAMS \u0026 WILKINS"}]}, "item_6_relation_47": {"attribute_name": "PubMed", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "21892103"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search\u0026DB=pubmed\u0026term=21892103", "subitem_relation_type_select": "PMID"}}]}, "item_6_relation_48": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.1097/JTO.0b013e31822e71c0"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1097/JTO.0b013e31822e71c0", "subitem_relation_type_select": "DOI"}}]}, "item_6_select_64": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_6_source_id_35": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1556-0864", "subitem_source_identifier_type": "ISSN"}]}, "item_6_source_id_39": {"attribute_name": "NII ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1556-0864", "subitem_source_identifier_type": "ISSN"}]}, "item_6_source_id_40": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA12058455", "subitem_source_identifier_type": "NCID"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Agatsuma, Toshihiko"}], "nameIdentifiers": [{"nameIdentifier": "17510", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Koizumi, Tomonobu"}], "nameIdentifiers": [{"nameIdentifier": "17511", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kanda, Shintaro"}], "nameIdentifiers": [{"nameIdentifier": "17512", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ito, Michiko"}], "nameIdentifiers": [{"nameIdentifier": "17513", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Urushihata, Kazuhisa"}], "nameIdentifiers": [{"nameIdentifier": "17514", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamamoto, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "17515", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hanaoka, Masayuki"}], "nameIdentifiers": [{"nameIdentifier": "17516", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kubo, Keishi"}], "nameIdentifiers": [{"nameIdentifier": "17517", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2015-09-25"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "H23Kou903_Agatsuma.pdf", "filesize": [{"value": "148.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 148400.0, "url": {"label": "H23Kou903_Agatsuma.pdf", "url": "https://soar-ir.repo.nii.ac.jp/record/7201/files/H23Kou903_Agatsuma.pdf"}, "version_id": "589b8a1a-cca1-4ace-b8be-fac5f368d69d"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Thymic carcinoma", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Chemotherapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Platinum", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Combination Chemotherapy with Doxorubicin, Vincristine, Cyclophosphamide, and Platinum Compounds for Advanced Thymic Carcinoma", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Combination Chemotherapy with Doxorubicin, Vincristine, Cyclophosphamide, and Platinum Compounds for Advanced Thymic Carcinoma", "subitem_title_language": "en"}]}, "item_type_id": "6", "owner": "1", "path": ["849"], "permalink_uri": "http://hdl.handle.net/10091/16022", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2012-10-01"}, "publish_date": "2012-10-01", "publish_status": "0", "recid": "7201", "relation": {}, "relation_version_is_last": true, "title": ["Combination Chemotherapy with Doxorubicin, Vincristine, Cyclophosphamide, and Platinum Compounds for Advanced Thymic Carcinoma"], "weko_shared_id": -1}
Combination Chemotherapy with Doxorubicin, Vincristine, Cyclophosphamide, and Platinum Compounds for Advanced Thymic Carcinoma
http://hdl.handle.net/10091/16022
http://hdl.handle.net/10091/16022e6988050-23f8-4b45-9f4f-f6b993fddf4b
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2012-10-01 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Combination Chemotherapy with Doxorubicin, Vincristine, Cyclophosphamide, and Platinum Compounds for Advanced Thymic Carcinoma | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Thymic carcinoma | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Chemotherapy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Platinum | |||||
資源タイプ | ||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | journal article | |||||
著者 |
Agatsuma, Toshihiko
× Agatsuma, Toshihiko× Koizumi, Tomonobu× Kanda, Shintaro× Ito, Michiko× Urushihata, Kazuhisa× Yamamoto, Hiroshi× Hanaoka, Masayuki× Kubo, Keishi |
|||||
信州大学研究者総覧へのリンク | ||||||
氏名 | Koizumi, Tomonobu | |||||
URL | http://soar-rd.shinshu-u.ac.jp/profile/ja.WakmHhkh.html | |||||
信州大学研究者総覧へのリンク | ||||||
氏名 | Urushihata, Kazuhisa | |||||
URL | http://soar-rd.shinshu-u.ac.jp/profile/ja.jakhHVkh.html | |||||
信州大学研究者総覧へのリンク | ||||||
氏名 | Yamamoto, Hiroshi | |||||
URL | http://soar-rd.shinshu-u.ac.jp/profile/ja.HVnhHVkh.html | |||||
信州大学研究者総覧へのリンク | ||||||
氏名 | Hanaoka, Masayuki | |||||
URL | http://soar-rd.shinshu-u.ac.jp/profile/ja.yCLmHVkh.html | |||||
出版者 | ||||||
出版者 | LIPPINCOTT WILLIAMS & WILKINS | |||||
書誌情報 |
JOURNAL OF THORACIC ONCOLOGY 巻 6, 号 12, p. 2130-2134, 発行日 2012-10-01 |
|||||
内容記述 | ||||||
内容記述タイプ | Other | |||||
内容記述 | This is a non-final version of an article published in final form in JOURNAL OF THORACIC ONCOLOGY. 6(12):2130-2134 (2011). | |||||
内容記述 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 信州大学博士(医学)・学位論文・平成23年3月31日授与(甲第903号)・吾妻俊彦 | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Introduction: Thymic carcinoma is a rare epithelial neoplasm that tends to be aggressive and metastasize widely. The optimal chemotherapy for unresectable advanced thymic carcinoma has not yet been established because of its rare occurrence. The purpose of this study was to evaluate the efficacy and tolerability of combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. Methods: A retrospective analysis of 34 patients with untreated and unresectable thymic carcinoma who received chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds between 1996 and 2010 was conducted. Twenty-nine patients were treated with a combination of cisplatin (50 mg/m(2)) and doxorubicin (40 mg/m(2)) on day 1, vincristine (0.6 mg/m(2)) on day 3, and cyclophosphamide (700 mg/m(2)) on day 4. Five patients were treated with carboplatin (area under the curve of 3.0 minutes center dot mg/ml) instead of cisplatin. Results: The responses of all 34 patients to the current regimen were assessed. The median number of treatment cycles for the present chemotherapy was 4. The overall response rate and disease control rate were 50.0% and 88.2%, respectively. The median survival was 21.3 months (95% confidence interval [CI], 15.0-37.2 months), and the 1-year and 3-year survival rates were 72.7% (95% CI, 56.8-88.6%) and 34.4% (95% CI, 16.2-52.6%), respectively. The most common adverse event was leukopenia/neutropenia, and nonhematological toxicities were mild. Conclusions: Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds is an effective and well-tolerated treatment for unresectable advanced thymic carcinoma. | |||||
資源タイプ(コンテンツの種類) | ||||||
内容記述タイプ | Other | |||||
内容記述 | Article | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1556-0864 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA12058455 | |||||
PubMed | ||||||
識別子タイプ | PMID | |||||
関連識別子 | http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=pubmed&term=21892103 | |||||
関連名称 | 21892103 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.1097/JTO.0b013e31822e71c0 | |||||
関連名称 | 10.1097/JTO.0b013e31822e71c0 | |||||
出版タイプ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
WoS | ||||||
表示名 | Web of Science | |||||
URL | http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000297974100023 |